Collegium Pharmaceutical Inc - Wutah pendapatan triwulanan COLL

Logo korporat perusahaan Collegium Pharmaceutical (COLL)

Collegium Pharmaceutical strictly adheres to ESG standards, monitoring raw materials and wastewater treatment. The business relies on stable demand from patients with chronic pain, which guarantees macro-resilience. Environmental initiatives focus on packaging recycling and drug disposal. The quarterly revenue growth trend clearly demonstrates income development, with this metric equal to 3.30.

COLL (Collegium Pharma) riwayat Owah-owahan pendapatan dibandhingake kuartal kepungkur saka 04.07.2022 nganti 20.11.2026

Ringkesan rincian data analitis Collegium Pharma (COLL)

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis wiwitan perusahaan:Collegium Pharmaceutical - COLL
Barang unggulan Collegium Pharmaceutical, Inc.

The business specifics of Collegium Pharmaceutical (COLL) are linked to regulatory pressure in the analgesics segment and legal risks regarding opioid litigation. By analyzing the pace of quarterly revenue growth, an investor assesses the percentage change in sales compared to the same period last year to confirm business resilience; however, a slowdown in this trend amid high share prices creates the risk of overpaying for the asset.